James Rubenstein, MD, PhD


An area of emphasis has been to define the molecular features of non-Hodgkin's lymphoma (NHL) of the central nervous system (CNS) using microarray technology. I have recently described the first gene expression profile analysis of CNS lymphoma and of circulating meningeal lymphoma cells and have defined genes which correlate with the refractory phenotype. To extend this analysis, I have collaborated with the C. David James laboratory at UCSF to develop an intracranial model of CNS lymphoma to systematically evaluate potential therapeutic targets in refractory lymphoma. In the near future we plan to evaluate novel pharmacologic agents which target protein kinase C-beta as well as Pim kinase(s). In addition, we plan to develop an orthotopic model using athymic or SCID mice to develop human CNS lymphoma xenografts to characterize putative lymphoma stem cells.

A second area of research has been the application of proteomic technology to define the CSF proteome in brain lymphoma to identify biomarkers which facilitate non-invasive diagnosis as well as prognosis. A third area of research has been to develop novel therapies for CNS lymphoma; one of these has been to develop the use of intraventricular rituximab as a component of therapy for this disease.